Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.
Li K, Zhong W, Fan J, Wang S, Yu D, Xu T, Lyu J, Wu S, Qin T, Wu Z, Xu L, Wu K, Liu Z, Hu Z, Li F, Wang J, Wang Q, Min J, Zhang Z, Yu L, Ding S, Huang L, Zhao T, Huang J, Lin T.
Li K, et al. Among authors: lyu j.
Nat Cancer. 2024 Sep 10. doi: 10.1038/s43018-024-00822-0. Online ahead of print.
Nat Cancer. 2024.
PMID: 39256488